Patients
At Syndax, we are advancing the next generation of targeted treatments to reimagine cancer care.
Every day is a new opportunity to demonstrate our passion for patients—a core value we lead with and one that unites us.
Syndax is a commercial stage oncology innovator developing first-in-class therapies. We are working to unlock the full potential of our pipeline to make progress on our mission.
Rearrangements of the KMT2A (mixed lineage leukemia or MLL) gene give rise to KMT2Ar acute leukemia that is known to have a poor prognosis. KMT2Ar acute leukemia can phenotypically appear as AML, ALL, or mixed phenotype acute leukemia (MPAL).
NPM1-mutant AML, which is distinguished by mutations in the NPM1 gene that drive the leukemic phenotype, is the most common type of cytogenetically normal adult AML. Similar to KMT2A-rearranged acute leukemia, NPM1-mutant AML is highly dependent on the expression of specific developmental genes that rely on the menin-KMT2A interaction. There are currently no approved therapies indicated for NPM1-mutant AML.
Chronic graft-versus-host disease (GVHD), an immune response of the donor-derived hematopoietic cells against recipient tissues, is a serious, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation which can last for years. Chronic GVHD typically manifests across multiple organ systems, with skin, joints/fascia and lungs being commonly involved and is characterized by the development of fibrotic tissue.
My whole world changed when I received my diagnosis for acute leukemia. I had myeloblasts in 96% of my bone marrow. I needed to get treatment right away. However, after two months of two different treatments with little response, I felt myself losing hope.
I asked my doctor what would happen if I failed my third treatment. He looked at me and said that people receive poor prognoses every day. I sat there, dumbstruck— and I was only 25. So, I left the hospital that very day and ultimately began my clinical trial experience.”
We recognize that enrollment in a clinical trial is not always possible for patients facing serious or life-threatening conditions such as cancer, and patients may therefore seek access to investigational medicines outside of a clinical trial. We seek to help patients who have not had success with existing, available therapies and may benefit from our investigational therapies currently in development.
For more information, you may find it helpful to reach out to the organizations listed below for information or support.
The organizations listed are independent of Syndax. The information/links provided are meant for informational purposes only.